| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.94▲ | 1.95▼ | 1.96▼ | 1.90▲ | 2.05▼ |
| MA10 | 1.95▼ | 1.97▼ | 1.97▼ | 1.91▲ | 2.25▼ |
| MA20 | 1.96▼ | 1.98▼ | 1.94▲ | 2.00▼ | 2.46▼ |
| MA50 | 1.98▼ | 1.92▲ | 1.94▼ | 2.27▼ | 3.07▼ |
| MA100 | 1.95▼ | 1.94▲ | 1.90▲ | 2.48▼ | N/A |
| MA200 | 1.91▲ | 1.92▲ | 2.15▼ | 2.79▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.009▼ | -0.001▼ | 0.018▲ | -0.009▼ |
| RSI | 40.322▼ | 45.629▼ | 50.135▲ | 44.689▼ | 39.704▼ |
| STOCH | 11.111▼ | 11.905▼ | 27.673 | 56.134 | 38.936 |
| WILL %R | -71.429 | -90.909▼ | -83.333▼ | -36.434 | -68.333 |
| CCI | -90.323 | -130.067▼ | -127.673▼ | 64.375 | -131.220▼ |
| MA | $HURA Price Crossed Above MA(7) | Set Alert |
|
Thursday, November 13, 2025 08:00 PM
Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, ...
|
|
Saturday, November 08, 2025 04:01 PM
Fintel reports that on November 14, 2025, Maxim Group maintained coverage of TuHURA Biosciences (NasdaqCM:HURA) with a Buy recommendation. As of November 9, 2025, the average one-year price target for ...
|
|
Wednesday, May 28, 2025 01:57 PM
TuHURA Biosciences targets immunotherapy resistance, a key unmet need, with promising early data. Cash constraints remain a significant risk, potentially undermining long-term investment returns even ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 05/12/25 | 1.99 | 2.04 | 1.93 | 1.94 | 82,672 |
| 04/12/25 | 1.91 | 2.00 | 1.91 | 1.98 | 85,461 |
| 03/12/25 | 1.81 | 1.91 | 1.80 | 1.91 | 105,500 |
| 02/12/25 | 1.85 | 1.91 | 1.81 | 1.81 | 115,000 |
| 01/12/25 | 1.94 | 1.98 | 1.84 | 1.84 | 130,000 |
| 28/11/25 | 2.09 | 2.14 | 1.98 | 2.00 | 65,776 |
| 26/11/25 | 1.96 | 2.1578 | 1.9401 | 2.09 | 204,127 |
| 25/11/25 | 1.93 | 1.955 | 1.8183 | 1.94 | 141,170 |
| 24/11/25 | 1.75 | 1.99 | 1.74 | 1.89 | 218,786 |
| 21/11/25 | 1.60 | 1.75 | 1.60 | 1.74 | 159,800 |
|
|
||||
|
|
||||
|
|